A Safety, Tolerability and Efficacy Study of ACE-011 in Patients With Osteolytic Lesions of Multiple Myeloma

Phase 2 Completed 30 enrolled Celgene Corporation

RandomizedParallel-groupDouble-blindTreatment

Summary

Multi-center, randomized, multiple-dose study to evaluate the safety, tolerability and efficacy of ACE-011 in patients with osteolytic lesions of multiple myeloma.

Timeline

Start: 2008-09-01
Primary completion: 2009-08-01
Completion: 2009-08-01

Publications

Background Abdulkadyrov KM, Salogub GN, Khuazheva NK, Sherman ML, Laadem A, Barger R, Knight R, Srinivasan S, Terpos E. Sotatercept in patients with osteolytic lesions of multiple myeloma. Br J Haematol. 2014 Jun;165(6):814-23. doi: 10.1111/bjh.12835. Epub 2014 Mar 21.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Sotatercept	Protein / enzyme biologic	0.1 mg/kg	Subcutaneous
Subject	Sotatercept	Protein / enzyme biologic	0.3 mg/kg	Subcutaneous
Subject	Sotatercept	Protein / enzyme biologic	0.5 mg/kg	Subcutaneous

A Safety, Tolerability and Efficacy Study of ACE-011 in Patients With Osteolytic Lesions of Multiple Myeloma

Summary

Timeline

Publications

Drugs

Indications